Skip to main content

Table 1 Tumor genomic next generation sequencing (NGS) study reveals mutations in several genes, including somatic mutations in genes mutated in the sebaceous carcinoma COSMIC dataset (in bold)

From: Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma

Gene

Alteration

Subcellular localization

Pathway

LRP1B

G3156C, Q1125*

Plasma membrane

Receptor mediated endocytosis

CCND1

S41L

Nucleus; cytosol

Cyclin D1, cell cycle

TET2

P174H

Nucleoplasm

DNA demethylation

TP53

rearrangement, del exon 10-11

Nucleoplasm

DNA repair

FANCA

A816V, R685S

Nucleus

DNA repair

FGF6

A63T

Extracellular

Growth factor

MYST3

Q1681_Q1684del

Nucleolus; cytosol

Histone acetyltransferase (HAT)

KRAS

G12C

Cytosol

MAPK signalling

RBM10

F173fs*7

Nucleus

mRNA splicing

MET

amplification

Plasma membrane

Receptor tyrosine kinase

FGFR3

I539del

Endoplasmic reticulum

Receptor tyrosine kinase

FLT4

K520E, R658W

Nucleus; plasma membrane

Receptor tyrosine kinase

ROS1

N692H

Vesicles

Receptor tyrosine kinase

TERT

-124C>T

Nucleoplasm

Telomerase

WT1

R471S

Nucleoplasm

WT1 Transcription Factor

MYC

L435F

Nucleoplasm

MYC Transcription Factor

ZNF703

G406R

Nucleus

Transcriptional co-repressor

c11orf30

C1211S

Nucleoplasm

Trascriptional Repressor

FLCN

R320Q

Nucleus; cytosol

Tumor suppressor

TNFAIP3

R706Q

Cytosol

Ubiquitination

  1. *denotes mutations causing a premature stop codon
  2. fs denotes the presence of a frameshift mutation